A pivotal study reported a benefit in overall survival and locoregional control in patients with localised head and neck cancer who were treated with both radiation and cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), over patients treated with radiation alone (Bonner et al, 2006). The gene discussed is EGFR; the disease is head and neck cancer.